Introduction
The treatment of tumors which fail radiation therapy has been a major clinical challenge, not only for head and neck tumors, but for other forms of cancers as well. Each year in the US approximately 40 000 individuals will be diagnosed with squamous cell carcinoma of the head and neck (SCCHN) and upper aerodigestive tract (American Cancer Society, 1993 ). This disease not only has a profound eect upon speech, swallowing and physical appearance, but has an overall survival rate of only approximately 50%, a rate which has remained relatively unchanged for more than 30 years (American Joint Committee on Cancer, 1983) .
Despite advances in current treatments, patients with advanced disease have a poor prognosis. More than two-thirds of the individuals in whom the diagnosis of SCCHN is made will present with stage III or stage IV disease (Dimery and Hong, 1993) at the primary and/ or nodal sites. Despite optimal local therapy, 50 ± 60% of these patients will ultimately develop local recurrence and 30% or more will develop distant metastatic disease. Treatment of recurrent disease no amenable to surgery is palliative at best and without long-term bene®t (Dimery and Hong, 1993) . Furthermore, the long-term outlook for those surviving their ®rst malignancy is overshadowed by a 10 ± 40% rate of a second primary malignancy (Dimery and Hong, 1993) . Treatment often requires aggressive adjunctive therapy after surgery, with radiation being the treatment or choice, either as a single modality, or as part of a multimodal course of treatment. Unfortunately, a signi®cant number of SCCHN have been found to be resistant to radiotherapy, a major factor in the high rate of recurrence observed for this type of malignancy. The development of an eective method for sensitizing SCCHN tumors to radiotherapy therefore, will have a profound eect on the treatment of this disease.
Mutant (mt) forms of the tumor suppressor gene p53 have been associated in a number of studies with poor clinical prognosis for malignancies such as carcinoma of the breast, lung, prostate, and bladder, soft tissue sarcoma, Wilm's tumor and various leukemias and lymphomas (reviewed in Chang et al., 1995; Newcomb, 1995) . p53 may also play a role in the development and progression of SCCHN. Depending upon the tissue source and method of detection of abnormal p53, both the gene and its expression have been identi®ed in 33% to 100% of head and neck cancers. Mutations have been found in exons 4 through 9 with a hot spot in the codon 238 ± 248 region (reviewed in Field et al., 1993; Brachman, 1994) . The presence of abnormal p53 may also correlate with a history of heavy smoking and drinking which are the primary environmental factors associated with SCCHN (Field et al., 1993) . Studies indicate that the presence of p53 mutations may also be indicative in SCCHN of a higher frequency of, and shorter median time to, recurrence of the tumor (Brachman, 1994) . In a recent study Shin et al. also reported that higher levels of mtp53 expression in primary SCCHN, due presumably to the stabilization and longer half-life of the mutant form of the protein, were associated with both earlier recurrence and development of second primary tumors and could be an important adverse prognostic factor for survival (Shin et al., 1996) .
A role for wild type (wt) p53 in the control of cellular proliferation by induction of programmed cell death (apoptosis) Clarke et al., 1993; Yonish-Rouach et al., 1991) and the regulation of cell cycle events (Kastan et al., 1991 Kuerbitz et al., 1992) has been established. Wtp53 has been found to induce apoptosis in mouse myeloid leukemia cells (Yonish-Rouach et al., 1991) . Furthermore, two separate groups of investigators using p53 knockout mice which lack wtp53 have demonstrated that thymocytes from these animals are resistant to g-radiation, or etoposide (a topoisomerase II inhibitor) induced apoptosis, whereas thymocytes from control mice with wtp53 showed radiosensitivity to g-irradiation Clarke et al., 1993) . Kastan and his colleagues (Kastan et al., 1991 Kuerbitz et al., 1992) demonstrated that after exposure to g-irradiation, cells containing wtp53 display a block in the G 1 phase of the cell cycle, while cells expressing only mutant (mt), or no p53, continued to progress through the cell cycle. It has more recently been suggested that p53 may play a role in the G 2 /M checkpoint as well (Powell et al., 1995; Russell et al., 1995; Stewart et al., 1995; Agarwal et al., 1995) .
The correlation between p53 and apoptosis, in conjunction with apparently normal development of mice lacking wtp53 (Donehower et al., 1992) , and the observations of a post-irradiation G 1 block, suggests that wtp53 functions in the regulation of the cell after DNA damage or stress rather than during proliferation and development. As the presence of mtp53 has also been shown to correlate with increased radiation resistance in some human tumors and cell lines (Agarwal et al., 1995; Donehower et al., 1992; Lee and Bernstein, 1993; O'Conner et al., 1993; McIlwrath et al., 1994) and a high percentage of head and neck tumors fail radiation therapy, it is conceivable that a cause and eect relationship exists between the lack of functional wtp53 found in a large number of SCCHN and this radiation resistance. The replacement of wtp53 may, therefore, ameliorate the high level of radiation resistance frequently observed in these cancers.
The development over the last few years of methods for the introduction of genes into cells in vivo has made such therapeutic interventions a possibility. Of these gene delivery systems, adenovirus vectors have been found to be particularly advantageous over traditional transfection methods and retroviral vectors for a number of reasons: (i) they have suciently high cloning capacity to accommodate most cDNAs; (ii) they can infect both replicating and quiescent cells; (iii) they can be grown to high titers and easily puri®ed (iv) they can be rendered replication defective; and (v) they can deliver DNA with high eciency both in vitro and in vivo (reviewed in Bramson et al., 1995) . In addition, adenovirus vectors are often preferable over retroviruses in that they are not subject to the possible adverse side eects which may be encountered due to genomic integration and deletion. Adenovirus also possesses a natural tropism for the epithelium of the aerodigestive tract which makes them particularly attractive in gene therapy for cancers of the head and neck region. Therefore, in spite of some disadvantages, such as the induction of immunogenicity, the use of an adenoviral construct to introduce wtp53 is a promising system for treating local SCCHN tumors and even the microscopic residual disease which is a major cause of the frequent post-surgical recurrence of this type of cancer.
In this study we have examined the ability of wtp53, introduced by means of an adenoviral construct (Av1p53), to sensitize SCCHN to radiation treatment both in an in vitro cell culture system and in an in vivo xenograft mouse model. Our ®ndings suggest that this is an eective means of sensitizing these tumors to radiation resulting in a greatly reduced rate of recurrence. Moreover, the sensitization of residual tumors through the combination of wtp53 and radiotherapy has the potential for use as a new therapeutic modality in the treatment of those tumors which initially failed radiation therapy, not only in cancers of the head and neck but in other forms of cancer as well.
Results

Eect of Av1p53 on in vitro cell growth
To determine if replacement of wtp53 could aect the growth of SCCHN tumor cells in an in vitro situation, exponentially growing SCCHN cell lines JSQ-3, SQ-20B and SCC61, were seeded at 3610 4 cells/well of a 24-well tissue culture plate. Twenty-four hours later, at approximately 50% con¯uency, the cells were treated with Av1p53 in doses varying from 10 to 320 (Jung et al., 1992) . Vacuolization was observed down to 10 MOI and by 80 MOI very few live cells were evident (Figure 2) . However, the only notable inhibition of cell growth by Av1LacZ4 in this cell line was with doses of 160 and 320 MOI (Figures 1 and 2 ) and that is still relatively insigni®cant in comparison to the eect of Av1p53. Radioresistant cell line SQ-20B, which was also derived from a tumor which failed radiotherapy, exhibits an alteration in the p53 gene expression (Jung et al., 1992 ). These cells showed a level of growth inhibition with Av1p53 similar to that observed in JSQ-3 cells (Figure 1 ). However, more growth inhibition by Av1LacZ4 was observed at high doses in these cells than in the JSQ-3 cells, indicating some nonspeci®c eect in this cell line. In contrast, both the p53 and LacZ containing adenovirus constructs had only minimal eect on the growth of radiosensitive SCCHN cell line SCC61, and that only at the highest doses (Figure 1 ). The p53 status of this cell line has not been determined.
More signi®cantly, treatment with either Av1p53 or Av1LacZ4 had no eect on the growth of a normal human ®broblast cell line (H500), which has been shown to contain only wtp53 (Srivastava et al., 1992) . Examination under higher magni®cation, as had been done for JSQ-3 cells, con®rmed this ®nding (data not shown). The clear area observed at 160 and 320 MOI with Av1p53 in these cells is an artifact which occurred during Giemsa staining ( Figure 1 ).
Also shown in Figure 1 is the eect of treatment with Av1p53 or Av1LacZ4 on human ovarian and breast carcinoma cell lines SK-OV-3 and SK-BR-3, respectively, both of which have mutant or no p53 (Johnson et al., 1991; Elstner et al., 1995) . The treatment protocol for these cell lines was identical to that used for the SCCHN lines. Both cell lines display a strong response to the replacement of wtp53. SK-BR-3 cells display not only growth inhibition, but almost complete cell killing at a dose of Av1p53 as low as 10 MOI. This cell line was also signi®cantly more sensitive to the LacZ containing adenoviral construct. SK-OV-3, while also highly sensitive to Av1p53, showed more speci®city in its response. Here, signi®cant growth inhibition and cell killing with Av1LacZ4 were observed only at the highest doses. These results indicate that the replacement of wtp53 is not just speci®c for SCCHN and may be an eective treatment for various types of cancer.
The replacement of wtp53 was shown by these experiments to eect the growth of JSQ-3 cells in a p53 speci®c manner. As mentioned above, these cells possess both a mtp53 gene and a radiation resistant phenotype. These cells therefore, are an ideal model with which to examine the usefulness of combining wtp53 gene therapy with radiotherapy in the treatment of SCCHN. Accordingly, the remainder of the studies described in this report employ this SCCHN tumor cell line.
In vitro sensitization to radiation treatment by Av1p53
The presence of a mutated form of p53 has been shown to correlate with increased radiation resistance in some human tumors and cell lines (Lee and Bernstein, 1993; . Therefore, the replacement of wtp53 may ameliorate the high level of radiation resistance frequently observed in head and neck cancers. We therefore examined the eect that replacement of wtp53 has on the radiation survival level of radiation resistant SCCHN cell line JSQ-3.
JSQ-3 cells were treated one time with 5, 10 or 20 MOI of Av1p53 for either 24 or 36 h and the D 10 values (radiation dose required to reduce survival to 10%) of the cells were compared to that of untreated JSQ-3 cells. As shown in Figure 3 , infection with Av1p53 was able to decrease the radioresistance level of JSQ-3 cells in a dose and time dependent manner. In all instances, a greater eect was observed when the cells were exposed to g-rays 36 h post-virus treatment compared to 24 h. However, with 20 MOI the D 10 value was reduced from the highly resistant level found in the control cells (6. Moreover, the large dierences in radioresistance levels seen before and after treatment with 20 MOI, and even 10 MOI (D 10 =4.63+0.12 Gy), of Av1p53 are statistically signi®cant (P50.001). In terms of survival, a decrease of almost 2 Gy represents a dramatic increase in sensitization to the killing eects of ionizing radiation. By comparison, the radiation As stated above, the radiation resistance level of the Av1p53 treated cells decreased with increasing time, up to 36 h after one viral treatment. However, by 48 h post-infection, the D 10 values began to increase. This rise was inversely proportional to Av1p53 dose, the amount of increase being smaller with increasing MOI (data not shown). Conversely, if two treatments with Av1p53 were given 24 h apart the decrease in radiation resistance observed at 36 h was maintained, or even ampli®ed 24 h after the second round of infection (data not shown). These ®ndings indicate that those cells which had not been transduced with the virus after one treatment continue to grow and maintain their initial radiation resistant phenotype thereby leading to an overall increase in resistance of the culture. A second virus treatment however, leads to an increased number of eected cells in the population, resulting in increased sensitization to ionizing radiation.
Expression of exogenous wtp53 protein in infected cells
To demonstrate that the virally transduced wtp53 is being expressed, the level of p53 protein in JSQ-3 cells was examined by Western blot analysis, using the pantropic anti-p53 monoclonal antibody Ab-2, 36 h post-infection with increasing doses of Av1p53. Thirtysix hours was chosen based upon the timing of the maximal reversal of radioresistance after one viral treatment as discussed above. As shown in Figure 5 , infection with increasing MOI of Av1p53 results in a concomitant increase in expression of the exogenous wtp53 (top band), as compared to uninfected JSQ-3 cells (C). An increase is also observed in the lower band, the endogenous mtp53 band, as viral dose increases. A similar observation was made by Liu et al. (1994) after treatment of two dierent SCCHN cell lines with a wtp53-adenoviral construct under control of the CMV promoter. Data indicates that, at least in murine cell lines, wild-type, but not mutant, p53 is capable of transactivating its own promoter through a sequence nearly identical to the NF-kB-binding site (Dee et al., 1993) . This increase in endogenous p53 may therefore be attributable to this transcriptional autoregulation. An increase in p53 expression often results in an induction of the WAF-1 gene, an important downstream eector of p53 function (ElDeiry et al., 1994) , which is involved in control of the cell cycle (Xiong et al., 1993; Harper et al., 1993) . We are currently examining the eect of introduction of wtp53 on WAF-1 expression in these cells. These results demonstrate that infection with Av1p53 results in production of immunoreactive p53 protein within the transduced cells in a dose dependent manner.
Enhancement of the eect of radiotherapy by wtp53 replacement in vivo
The results described above indicated that treatment with Av1p53 was able to individually aect both tumor growth and the level of radiation resistance in vitro. The clinical relevance of this form of gene therapy would be greatly enhanced if synergism between replacement of wtp53 and radiation therapy could be demonstrated in vivo. Such an eect may result in a reduction of the dose of radiation required for eective To ascertain the eectiveness of the combination therapy, 4 ± 6 week old female athymic nude mice were injected subcutaneously on the lower back above the tail with 1.5610 6 JSQ-3 cells in 50 ml PBS. PFU of the control Av1LacZ4 was injected into one group and one goup was left untreated. Thirty-six to forty-eight hours post injection, the tumor area only was exposed to a 2.5 Gy dose of ionizing radiaton. Thereafter, the animals were given 2.5 Gy of radiation every 48 h to a total dose of 20 Gy. For comparison, a group of untreated mice and mice which had been treated with Av1p53, or Av1LacZ4, received no radiation.
The ®ndings presented in Figure 6a ± c demonstrate that the combination of radiation and wtp53 replacement is markedly more eective in controlling tumor growth than either treatment individually. In the animals treated with radiation alone, the tumors initially regressed (Figure 6a) . However, in a manner analogous to that observed in the clinical situation, these tumors began to recur by approximately 5 weeks post-radiation. Similarly, those treated with radiation and a high dose (1.5610 9 PFU) of the control Av1LacZ4 also regressed, and then began to regrow at about 7 weeks post-treatment.
In contrast, treatment with the combination of radiation and the adenoviral construct containing wtp53 resulted in complete eradication of the tumors. With the exception of those tumors treated with the lowest dose of Av1p53 (2.5610 8 PFU) (Figure 6b ), these tumors did not recur even 5 months after the last dose of radiation was administered. This observation is represented in Figure 6b where the plots for Av1p53 at 5610 8 , 1610
9 and 1.5610 9 PFU go to zero between days 42 to 65 and remain at zero for the duration of the experiment. This is in striking contrast to the plots for 1.5610 9 PFU of Av1LacZ4 ( Figure 6a ) and 2.5610 8 PFU of Av1p53 (Figure 6b ), both of which begin to regrow at about 65 ± 72 days post-virus infection (approximately 50 days post-irradiation).
In the unirradiated tumors (Figure 6c ), treatment with the three lower doses of Av1p53 alone had only minimal inhibitory eect on tumor growth. Although the highest dose of Av1p53 (1.5610 9 PFU) was able to induce signi®cant tumor regression for a prolonged period of time, these tumors also began to recur and reached approximately 50% of their initial volume by 162 days after Av1p53 treatment (Figure 6c ). Four separate in vivo experiments of this nature have been performed with consistent results.
Histochemical staining of xenograft tumors after combination therapy
Subcutaneous xenograft tumors and surrounding tissues were removed, ®xed, sectioned, and stained with hematoxilin and eosin (H&E) for evaluation of their histological appearance, with or without the combination of Av1p53 and radiation treatment. The control untreated, unirradiated tumor is shown in Figure 7a . The xenograft exhibited characteristics of squamous cell carcinoma, with keratin pearls and desmosomes. Two injections (48 h apart) with 1610 8 PFU Av1p53 without radiation was able to induce some morphological changes as indicated by the condensation of the chromatin leaving empty space (vacuoles) within the con®nes of the nuclear membrane. Some tumor cells also appeared more differ- A synergistic eect is clearly seen, however, when gene replacement therapy and radiation are combined. Only very few pyknotic cells (mostly cell debris) at the site previously bearing tumor are present after treatment with 5610 7 PFU of Av1p53 in combination with 20 Gy of radiation (Figure 7e ). Even more striking is the appearance of the tumor tissue remaining after two treatments with 1610 8 PFU of Av1p53 and 20 Gy (Figure 7f ). In the very small residual tumor tissue, there are no live tumor cells and only necrotic tissue is present. The results of these studies suggest a synergistic eect when wtp53 replacement is used in concert with standard radiotherapy (compare panels b, c and f).
Discussion
SSCHN can be dicult to treat with a high rate of local recurrence. This is due primarily to the presence of microscopic residual tumor after surgery at the site of the primary tumor and the resistance of a signi®cant percentage of these tumors to radiation, the most common form of adjuvant therapy for this disease. Since it appears that most anti-cancer agents work by inducing apoptosis (Kerr et al., 1994) , inhibition of, or changes in the pathway can conceivably lead to failure of therapeutic regimens. The role of the p53 tumor suppressor gene in inducing apoptosis in response to stress is well established. Moreover, a direct link has been suggested between mutations in p53 and resistance to cytotoxic cancer treatments, (both chemo-and radiotherpay) (Lowe, 1995) . It has also been suggested that the loss of wtp53, which is essential for the eective activation of apoptosis following irradiation or treatment with chemotherapeutic agents, may contribute to the cross-resistance to anticancer agents observed in some tumor cells (Johnson et al., 1991) . For example, various laboratories have established a correlation between the presence of mtp53 and chemoresistance in mouse ®brosarcomas and in primary tumor cultures from human gastric, esophageal and breast carcinomas as welll as b-cell chronic lymphoblastic leukemia (Koechli et al., 1994; Silber et al., 1994; Nabeya et al., 1995) . Wu and El-Deiry (1996) , Lutzker and Levine (1996) and Aas et al. (1996) have recently associated p53 status with the eectiveness of chemotherapeutic agents in ovarian teratocarcinomas, testicular teratocarcinomas and breast cancer (respectively). In addition, chemosensitivity, along with apoptosis, was restored by expression of wtp53 in non-small cell lung carcinoma mouse xenografts carrying mtp53 (Fujiwara et al., 1994) . However, the presence of some A p53 sensitizes head and neck cancer to radiotherapy KF Pirollo et al con¯icting reports, (Wahl et al., 1996; Hawkins et al., 1996) indicate that the relationship between p53 and chemoresistance may have a tissue or cell type-speci®c component.
The lack of G 1 block, due to the presence of mtp53, has been shown, particularly in cells of hematopoietic lineage, to correlate with an increase in radiation resistance (Lee and Bernstein, 1993; O'Conner et al., 1993) . Moreover, McIlwrath et al. (1994) measured the G 1 arrest in 12 human tumor cell lines displaying a wide range of radioresponsiveness. They found a signi®cant inverse correlation between the level of ionizing radiation-induced G 1 arrest and radiation resistance, i.e. cell lines lacking G 1 arrest were radioresistant. Since abnormal p53 has been detected in SCCHN at a high frequency, there is likely to be a correlation between this and the high percentage of radiation resistance observed in these tumors. However, the relationship between p53 status and the radiation resistant phenotype is not entirely clear and may not completely or directly correlate for ®broblast cells or all tumor cell lines (Jung et al., 1992; Kasid et al., 1993) .
The introduction of wtp53 has been reported to suppress, both in vitro and in mouse xenograft models, the growth of various types of malignancies including SCCHN. In in vivo studies in nude mice with established subcutaneous SCCHN nodules, Liu et al., demonstrated that peritumoral injection of a wtp53 carrying adenovirus was able to signi®cantly reduce tumor growth (Liu et al., 1994) . Moreover, Clayman et al. was able to prevent the establishment of SCCHN tumors in nude mice for 12 weeks by introducing wtp53-adenovirus no more than 48 h after subcutaneous implantation of 2.5610 6 cells . The induction of apoptosis by the transduced wtp53 was shown by these investigators to play a role inhibiting tumor formation in this xenograft model . Other investigators have observed similar growth inhibition by introduction of wtp53 in, for example, prostate Srivastava et al., 1995) , colon (Shaw et al., 1992) , and lung tumor cells (Fujiwara et al., 1993 (Fujiwara et al., , 1994 . Many of these studies employed adenoviral vectors as the vehicles for introduction of the wtp53 (Liu et al., 1994 Fujiwara et al., 1994; Clayman et al., 1995; Srivastava et al., 1995; Shaw et al., 1992) . The use and advantages of adenovirus for gene therapy have been recently reviewed (Bramson et al., 1995; Blau et al., 1995; Stewart, 1995) . Due to its natural anity for the epithelium of the aerodigestive tract, adenovirus is the best vehicle currently available for gene therapy studies of head and neck cancer.
In the studies described above, we employed an adenoviral vector carrying wtp53 (Av1p53) under control of the RSV promoter, to determine if replacement of wtp53 could sensitize radiation resistant SCCHN tumors to radiotherapy. Consistent with previous reports (Liu et al., 1994 Fujiwara et al., 1994; Clayman et al., 1995; Srivastava et al., 1995; Shaw et al., 1992) , we also found that introduction of wtp53 was capable of inhibiting cell growth in tumor cell lines known to have an aberrant form of the gene. In contrast, Av1p53 had virtually no eect on a normal human ®broblast cell line which carries only wtp53. More signi®cantly, replacement of wtp53 was able to revert the radiation resistant phenotype of SCCHN cell line JSQ-3 in a dose and time dependent manner. These results support the hypothesis that the eectiveness of therapeutic agents is determined, at least in part, by a p53-dependent mechanism (Lowe, 1995) . Since it is known that wtp53 can promoter apoptosis (Oren, 1994) , it is possible that the increase in radiation sensitivity observed here after introduction of wtp53 may be related to a restoration of the apoptotic pathway in these cells. Hallahan et al. also observed a decrease in tumor growth, an induction of apoptosis and a sensitization to radiation treatment after infection of xenografts of SCCHN cell line SQ-20B with an adenovirus containing the gene for TNF-a under control of the radiation inducible promoter Egr (Hallahan et al., 1995) . Therefore, induction of apoptosis by cytotoxic agents, such as TNF-a, or the restoration of the apoptotic pathway by replacement of wtp53, may play a signi®cant role in controlling tumor growth.
From a clinical standpoint, the sensitization of the tumor to radiotherapy after treatment with wtp53 is signi®cant. As demonstrated in our in vivo studies, the combination of gene therapy with wtp53 and conventional radiotherapy was markedly more eective than either treatment alone. This combined modality was able to regress completely and prevent recurrence of established tumors for over 5 months when a radiation dose of only 20 Gy was administered concomitantly with as little as 5610 8 PFU of wtp53-adenovirus. In the clinical setting, radiation doses of 65 to 75 Gy for gross tumor and 45 to 50 Gy for microscopic disease are commonly employed in the treatment of cancer of the head and neck (Awan et al., 1991) . Even so, 50 ± 60% of these patients will ultimately develop local recurrence (Dimery and Hong, 1993) . Given the adverse side eects associated with high doses of radiation, radiosensitization of these tumors, resulting in a decrease in the amount of radiation necessary to p53 sensitizes head and neck cancer to radiotherapy KF Pirollo et al be eective, would be of immense bene®t to the patient. Furthermore, restoration of wtp53 function in tumors which had previously failed radiotherapy would sensitize these tumors and thus allow further therapeutic intervention.
Besides their many advantages, there are also disadvantages to the potential use of adenoviral vectors for gene therapy. The current generation of vectors are immunogenic and induce a non-speci®c in¯ammatory response and antiviral cellular immunity Setoguchi et al., 1994; Yang et al., 1994 . Therefore, repeated administration may not be feasible. In this respect our ®ndings that, when used in concert with conventional radiotherapy, one administration of Av1p53 was sucient to have a therapeutic eect is of great consequence.
It is unlikely that 100% of the cells in the xenograft tumors were transduced by the virus. How, therefore, do we account for the eectiveness of our in vivo studies? It has been postulated that adenoviral vectors containing wtp53 control cell growth partially through a`bystander eect' which may be related to the induction of apoptosis by the wtp53. It is conceivable, therefore, that this`bystander eect' may be a contributory factor to the eectiveness of the combination therapy. However, very little is known at this time concerning the mechanism and pathway involved in this process for p53. It has been speculated that some as yet unknown apoptotic signal may be contained within the vesicles which result from apoptosis and which are ultimately phagocytized by neighboring cells (Seachrist, 1994) . Alternatively, this apoptotic signal may be transferred through gap junctions, as is believed to be the case for phosphorylated gancyclovir with the HSV-TK gene (Seachrist, 1994; Pitts, 1994) . Work is currently in progress to examine this question. The presence of p53 mutations have also been linked to resistance to chemotherapeutic agents (Lowe, 1995; Koechli et al., 1994; Silber et al., 1994; Nabeya et al., 1995) . Furthermore, Fujiwara demonstrated that expression of wtp53 in p53-de®cient lung cancer cells was able to restore chemosensitivity (Fujiwara et al., 1994) . Therefore, the use of wtp53 gene therapy, not as a single modality, but in combination with conventional radio-and/or chemotherapy holds promise as a new, more eective means of treating not only a wide variety of primary malignancies but also as a means to sensitize residual or recurring tumor to further therapeutic intervention.
Materials and methods
Cell culture
Human head and neck cell lines JSQ-3, derived from a tumor of the nasal vestibule (Weichselbaum et al., 1988) , SQ-20-B, derived from a squamous cell carcinoma of the larynx (Weichselbaum et al., 1986) and SCC61 derived from an oral (tongue) tumor (Weichselbaum et al., 1986) were generous gifts from Dr Ralph Weichselbaum, University of Chicago. These cell lines along with human non-cancerous skin ®broblast cell line H500, were maintained in Minimum Essential Medium with Earle's salts (EMEM), supplemented with 10% heat-activated fetal bovine serum; 50 mg/ml each of penicillin, streptomycin and neomycin; 2 mM L-glutamine; 0.1 mM non-essential amino acids and 1 mM sodium pyruvate. Human breast (SK-BR-3) and ovarian (SK-OV-3) carcinoma cell lines (obtained from ATCC, Rockville, MD) were maintained in McCoy's 5A medium supplemented with 10% fetal bovine serum, 50 mg/ml each of penicillin, streptomycin and neomycin and 2 mM L-glutamine. For in vitro viral infection, the cells, at approximately 30 ± 50% con¯uency, were incubated with either Av1p53 or Av1LacZ4, diluted to the appropriate viral concentration with 150 ± 500 mL Phosphate buered saline (PBS), at 378C with gentle rocking. At the end of 2 h, fresh medium was added without removal of the virus.
In vitro radiobiology
Cellular response to radiation was evaluated by the cell survival assay. Exponentially growing monolayer cultures of each cell line were virally infected as described above. The cells were harvested 24, 36, or 48 h later, suspended in fresh medium and irradiated at room temperature with graded doses of 137 Cs g-rays at a dose of approximately 36 Gy/min in a JL Shepard and Associates Mark I irradiator. Afterward, the cells were diluted and plated at a concentration of 500 to 5000 cells per well in a 6-well tissue culture plate. Two to three days after plating, the plates were supplemented with 0.5 ml of fetal bovine serum plus 5 mg/ml hydrocortisone. Approximately 7 ± 14 days later, the plates were stained with 1% crystal violet and colonies (comprising 50 more cells of normal appearance) were scored. Survival curves were plotted as the log of the survival fraction versus the radiation dose using Sigma-Plot Graphics program. D 10 (the dose required to reduce survival to 10%) values were calculated from the initial survival data.
Protein analysis
Cells for p53 protein analysis were trypsinized, pelleted, rinsed with PBS and lysed in RIPA buer (1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 30 mg/ml aprotinin and 1 mM sodium orthovanidate in PBS) (Santa Cruz Biotechnology, Inc). After shearing with a 26 gauge needle, 100 mg/ ml Phenylmethylsulfonyl¯uoride (PMSF) was added, the lysate incubated on ice for 30 ± 60 min and centrifuged at 13 000 g for 20 min at 48C to pellet insoluble material. Protein concentration was determined using the micro-BCA Protein Assay Kit (Pierce Biochemicals).
Forty mg of protein lysate was mixed with an equal volume of 26 protein sample buer (0.05 M Tris (pH 6.8), 3% SDS, 20% Glycerol, 6% 2-Mercaptoethanol and 0.001% Bromophenol blue) boiled for 5 min, loaded on a 10% (4% stacking gel) SDS/Polyacrylamide gel and electrophoresed at 200 V for 8 h. The protein was transferred to nitrocellulose membrane as previously described (Janat et al., 1994) . Preparation of membrane and incubation with the primary and secondary antibodies was performed essentially as described in a protocol supplied by Santa Cruz Biotechnology, Inc, with the exception that incubation with the primary antibody (Anti-p53 antibody Ab-2, Oncogene Research Products) was extended to 2 h, with wash times of 15 min per wash. The washings after addition of the secondary antibody (Anti-mouse IgG-HRP, Santa Cruz Biotechnology, Inc) were also lengthened to 15 min per wash.
Visualization of the protein was accomplished using the ECL Western Blotting Kit (Amersham) according to the manufacturer's protocol.
Adenoviral vectors
The adenoviral vectors employed in the study, Av1p53 and Av1LacZ4, were constructed at Genetic Therapy, Inc/ Novartis, Gaithersburg, MD and are replication de®cient, Ela/Elb, E3 deletion mutants containing a wtp53 gene, and a LacZ (b-galactosidase) gene, respectively.
Construction of Av1LacZ4 has previously been described Trapnell, 1993; Mittereder et al., 1994) . Av1p53 was constructed as follows: Plasmid pBSK-SN3, obtained from PharmaGenics (Allendale, NJ), contains a 1.8 kb XbaI fragment that includes the wild-type p53 open reading frame as well as 5' and 3' untranslated regions cloned into the XbaI site of Bluescript SK (Strategene, La Jolla, CA). pBSK-SN3 was digested with SmaI and partially digested with NcoI to generate a 1322 bp fragment containing the p53 open reading frame. The fragment was gel puri®ed and ligated into plasmid pBg in place of the bgalactosidase gene between the NcoI the XhoII sites to yield plasmid pp53. Av1p53 was constructed by ligation of a 1.4 Kb NotI ± SmaI fragment of pp53, which contains the open reading frame of wtp53 and approximately 140 bp of 3' untranslated region, to the EcoRV fragment of PAVS6 (Mittereder et al., 1994) to create pAVS6p53 (Figure 8a ). pAVS6p53 contains the adenoviral inverted terminal repeat (ITR) and packaging signal, the Rous Sarcoma Virus (RSV) promoter, the adenoviral tripartite leader, the human p53 open reading frame, the SV40 polyadenylation signal, the adenoviral homologous recombination region and the ampicillin resistance gene. This plasmid was subsequently linearized with NotI, followed by homologous recombination with the large ClaI fragment of wild-type adenovirus Add1327 according to the same procedure as described for the generation of Av1LacZ4 from pAVS6n-LacZ Trapnell, 1993; Mittereder et al., 1994) (Figure 8b ). This ClaI fragment contains all the adenoviral genes except the ITR, the Ela enhancer/packaging region and the Ela gene. Viral stocks were propagated in 293 cells and titered by plaque assay (Mittereder et al., 1994) . Speci®cally, the pAVS6p53 expression plasmid was linearized with NotI and gel puri®ed. The Ad-d1327 ClaI fragment (2.5 mg) and 5 mg of linearized pAVS6p53 plasmid were introduced into 293 cells by calcium phosphate transfection (BRL kit). Viral DNA from ten plaques was isolated and digested with BglII and ClaI to generate a 1.4 kb p53 fragment. Digested DNA was fractionated on a 1% agarose gel and transferred to nitrocellulose for Southern hybridization with a radiolabeled p53 speci®c probe. The crude viral lysate (CVL) from a p53 positive plaque was used to make a large scale preparation of Av1p53 which was puri®ed by CsCl banding using standard methods. This preparation of Av1p53 was then plaque puri®ed twice by limiting dilution in 293 cells. Ten plaques were isolated and ampli®ed on 293 cells to generate CVL.
The viral DNA prepared from each CVL was used in a PCR reaction to amplify a 1.6 kb fragment containing the p53 gene. One of these p53 positive plaques was then used to make large scale preparations of Av1p53.
Growth of human xenograft tumors in vivo 1.0 ± 1.5610 6 human SCCHN tumor cells (JSQ-3) in 50 ml PBS were injected subcutaneously on the lower back above the tail of 4 ± 6 week old female athymic nude (athymic NCr-nu)mice. When xenografts of the predetermined size were evident at the injection site, the animals were divided into groups. Each group (4 ± 8 mice/group) was injected one time, directly into the tumor, with 2.5610 8 to 1.5610 9 PFU of the Av1p53 or Av1LacZ4 (in 50 ml PBS). Control tumors were not injected. 36 ± 48 h post injection, the animals were immobilized in a lead chamber which shielded the body except for the tumor area which was exposed to a 2.0 ± 2.5 Gy dose of ionizing radiation using a Philips RT 250, 250 Kv X-Ray machine using a 0.5 mmCu ®lter with a dose rate of 84 cGy/min. Thereafter, the animals were given 2.0 ± 2.5 Gy of radiation every 48 h to a total dose of 20 ± 25 Gy. For comparison, one group of untreated tumors, as well as tumors which had been injected with Av1p53 or Av1LacZ4, received no irradiation. The size of each tumor was measured prior to viral infection and to each radiation treatment and weekly thereafter. Data was calculated as the percent of the original tumor volume present prior to the viral injection at day 0.
